Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

References

Page 1

	Year	Citations
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Fernando P. Polack, Stephen J. Thomas, Nicholas Kitchin, New England Journal of Medicine	2020	15.1K
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine New England Journal of Medicine	2020	10.4K
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report Lisa A. Jackson, Evan J. Anderson, Nadine Rouphael, New England Journal of Medicine	2020	3.4K
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Jennifer M. Dan, José Mateus, Yu Kato, Science	2021	3K
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates Edward E. Walsh, Robert W. Frenck, Ann R. Falsey, New England Journal of Medicine	2020	2.7K
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, The Lancet VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	2.6K
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity Carolyn Rydyznski Moderbacher, Sydney I. Ramirez, Jennifer M. Dan, Cell	2020	1.9K
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, The Lancet VaccinationVaccine SafetyVaccinologyInterim AnalysisVaccine Development	2021	1.8K
Evolution of antibody immunity to SARS-CoV-2 Christian Gaebler, Zijun Wang, Julio C. C. Lorenzi, Nature	2021	1.7K

Page 1